Windlas Biotech Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
- June 16, 2026
- Posted by: Neeraj Pandey
- Category: News
Windlas Biotech CMP: Rs 825.5 (2026). 52W High: Rs 1,098. 52W Low: Rs 697. Mkt Cap: Rs 1,702 Cr. P/E: 25.6. Analyst Consensus: Rs 960.
The Windlas Biotech stock prediction for 2026 from leading brokerages covers a range reflecting sector dynamics, earnings trajectory and the macro environment. All estimates may or may not be achieved. Treat any Windlas Biotech share price prediction as one data point and not as a guarantee of future performance.
This article reviews every dimension of the Windlas Biotech stock forecast analysts are tracking, including key drivers, bull and bear scenarios and the primary risks. Verify all figures with the latest brokerage reports before any investment decision.
Click Here – Get Free Investment Predictions
What Analysts Predict for Windlas Biotech Stock in 2026
Analyst consensus on the Windlas Biotech stock prediction for 2026 is tracked by leading brokerages. The table below shows the latest available data from JM Financial and ICICI Securities. All figures are sourced from publicly available research and should be verified before publishing.
| Brokerage | Rating | Windlas Biotech Stock Prediction (Rs) | Updated |
|---|---|---|---|
| JM Financial | Buy | Rs 980 | 2026 |
| ICICI Securities | Buy | Rs 940 | 2026 |
| Analyst Consensus | — | Rs 960 | 2026 |
The Windlas Biotech stock prediction range reflects genuine difference of opinion on demand recovery, margin trajectory and sector headwinds. The implied upside in the Windlas Biotech stock forecast from the current price of Rs 825.5 may or may not be realised by end of 2026.
3 Stocks Building Serious Momentum Right Now
When Univest analysts identify high-conviction stock opportunities, investors pay attention.
Our research team has shortlisted the Top Stocks to Buy based on current market momentum, sector trends & growth potential for 2026.
- Discover stocks investors are actively accumulating
- High-conviction opportunities backed by research
- Designed for the next phase of market growth
Unlock the latest Top Stock Picks now on Univest
Windlas Biotech Company Overview
Windlas Biotech is a significant player in India’s pharmaceutical industry with a presence across domestic formulations, US generics and specialty segments. The Windlas Biotech stock prediction for 2026 reflects both the pipeline growth potential and regulatory risk.
| Metric | Value |
|---|---|
| NSE Ticker | WINDLAS |
| Sector | Pharmaceuticals and Healthcare |
| CMP | Rs 825.5 (2026) |
| 52 Week High | Rs 1,098 |
| 52 Week Low | Rs 697 |
| Market Cap | Rs 1,702 Cr |
| P/E Ratio | 25.6 |
| Windlas Biotech Stock Prediction Consensus (12M) | Rs 960 |
Windlas Biotech Stock Prediction by Time Horizon
Analysts split the Windlas Biotech share price prediction across time frames as near-term drivers differ materially from the long-term view.
Short-Term Windlas Biotech Stock Prediction
The near-term Windlas Biotech stock forecast reflects current sentiment, sector news and upcoming earnings prints. Key support and resistance levels around Rs 825.5 are being watched closely. A short-term Windlas Biotech share price prediction carries the most uncertainty of any time horizon.
12-Month Windlas Biotech Stock Prediction
JM Financial targets Rs 980 (Buy) and ICICI Securities targets Rs 940 (Buy). Most desks refresh their Windlas Biotech stock forecast within two to four weeks of each quarterly earnings print. The Windlas Biotech share price prediction should be verified against the most recent analyst reports.
Long-Term Windlas Biotech Stock Prediction
The long-term Windlas Biotech stock prediction is built on assumptions about demand recovery, margin expansion and revenue diversification in the Pharmaceuticals and Healthcare sector. The long-term Windlas Biotech share price prediction carries the most uncertainty and should be treated as directional guidance only.
Windlas Biotech Stock Forecast: Key Factors
The following four factors appear consistently in research reports on the Windlas Biotech stock prediction and are the primary inputs into the bull and bear case scenarios.
US Generic Revenue
US generics revenue is the most watched metric in the Windlas Biotech stock forecast. USFDA approval timelines and price erosion rates directly affect the Windlas Biotech share price prediction from most research desks.
Domestic Formulations Growth
Domestic formulation growth provides a stable base that supports the Windlas Biotech stock prediction even when export growth faces headwinds.
R&D Pipeline
The depth and commercialization pace of the R&D pipeline is a key variable in the long-term Windlas Biotech share price prediction. New product approvals are cited as catalysts for the Windlas Biotech stock prediction.
EBITDA Margin
Sustained EBITDA margin expansion is typically the basis for the bullish Windlas Biotech stock forecast. Margin recovery strengthens the Windlas Biotech share price prediction from most research desks.
Windlas Biotech Stock Prediction: Bull and Bear Scenarios
| Scenario | Windlas Biotech Stock Prediction | Key Conditions |
|---|---|---|
| Bull Case | Rs 980 | Strong execution, margin improvement, favourable macro and sector re-rating |
| Base Case | Rs 960 | Steady performance, gradual recovery, margins hold, growth on track |
| Bear Case | Rs 697 | Demand deterioration, margin pressure, sector de-rating and macro headwinds |
The bull case Windlas Biotech stock forecast of Rs 980 assumes most positive variables converge. The base case of Rs 960 is the analyst consensus and may or may not be achieved.
How Analysts Are Reading the Windlas Biotech Stock Story
Analyst reviews of the Windlas Biotech share price prediction highlight the company’s core strengths in Pharmaceuticals and Healthcare alongside near-term headwinds from macro uncertainty, competitive pressure and sector-level challenges. Overall the Windlas Biotech stock prediction consensus is built on real business strengths set against real risks.
Key Risks to the Windlas Biotech Stock Prediction
USFDA Regulatory Risk
Import alerts and warning letters from the USFDA are the most significant risks to the Windlas Biotech stock prediction. A facility closure would force an immediate sharp revision to the Windlas Biotech share price prediction.
Price Erosion in the US
Pricing pressure in US generics compresses the revenue per product and affects the Windlas Biotech stock forecast. Aggressive price erosion pushes the Windlas Biotech share price prediction toward the bear case.
R&D Execution Risk
Delays in clinical trials or approval failures affect the Windlas Biotech stock prediction. The Windlas Biotech share price prediction is particularly sensitive to key pipeline asset announcements.
Currency Risk
A strengthening rupee against the dollar reduces export realisation and affects the Windlas Biotech stock forecast. Currency risk is embedded in conservative Windlas Biotech share price prediction models.
How to Monitor the Windlas Biotech Stock Forecast
Track the Windlas Biotech share price prediction consensus quarterly. After every earnings release, most brokerages revise their Windlas Biotech stock forecast within two weeks. Comparing the revised Windlas Biotech stock prediction to the previous estimate tells you whether analyst sentiment is improving or deteriorating.
Compare the current price of Rs 825.5 with the analyst target range of Rs 980 to Rs 940. A wide Windlas Biotech stock prediction band reflects genuine uncertainty, so position size should reflect that range rather than the midpoint alone.
Review the Windlas Biotech share price prediction every quarter against key business metrics for the Pharmaceuticals and Healthcare sector. A single estimate from any analyst is a point-in-time view and should be treated as one input among many when making any investment decision.
Check Live Windlas Biotech Fundamentals on the Univest Screener
Conclusion
The Windlas Biotech stock prediction for 2026 reflects the analyst community’s assessment of Windlas Biotech’s competitive position, earnings trajectory and macro environment. JM Financial holds a Buy stance with a target of Rs 980 while ICICI Securities has a Buy rating with a target of Rs 940, giving an analyst consensus of Rs 960.
The Windlas Biotech stock forecast is set against near-term risks that make the Windlas Biotech share price prediction range wide. Investors should verify any estimate with the latest brokerage reports before using it as an investment reference. The analyst forecast will be revised after every quarterly result, so tracking changes in the Windlas Biotech stock prediction over time is more valuable than relying on any single estimate.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.
Download the Univest iOS App or Univest Android App to track the live Windlas Biotech stock prediction and share price prediction changes in real time.
Disclaimer: Data and figures in this article are sourced from publicly available information and may or may not be accurate. Analyst price targets are from public brokerage reports and should be independently verified. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Windlas Biotech Stock Prediction 2026
What is the Windlas Biotech stock prediction for 2026?
Ans. The Windlas Biotech stock prediction for 2026 is based on analyst consensus from JM Financial and ICICI Securities. The consensus target is Rs 960. All estimates may or may not be achieved.
Is the Windlas Biotech stock prediction bullish or bearish?
Ans. JM Financial has a Buy rating with target Rs 980. ICICI Securities has a Buy rating with target Rs 940. The Windlas Biotech stock forecast reflects genuine analyst diversity of opinion.
What is the Windlas Biotech share price prediction based on fundamentals?
Ans. The Windlas Biotech share price prediction rests on the US generic pipeline, domestic growth, EBITDA margin and regulatory compliance track record. Analysts tracking Windlas Biotech closely cite these as the primary drivers of the 2026 outlook.
What is the long-term Windlas Biotech stock prediction?
Ans. The long-term Windlas Biotech stock prediction assumes the company sustains its core business drivers over a multi-year horizon. The 12-month consensus of Rs 960 is the nearest reliable anchor point.
What are the key risks to the Windlas Biotech stock prediction?
Ans. The primary risks include sector-specific headwinds, macro uncertainty, regulatory changes and competitive pressure. Every Windlas Biotech stock prediction should be read alongside its risk assumptions.
What does the Windlas Biotech stock forecast say for 2026?
Ans. JM Financial: Buy target Rs 980. ICICI Securities: Buy target Rs 940. These Windlas Biotech share price prediction estimates may or may not prove accurate.
Where can I track the latest Windlas Biotech stock prediction?
Ans. Track the latest Windlas Biotech stock prediction on the NSE and BSE websites and on the Univest app and screener for live price and updated analyst targets.
